SecurityHART / Harvard Apparatus Regenerative Technology, Inc. (09074M103)
IndustrySurgical and Medical Instruments and Apparatus
Common Shares Outstanding2,859,419 shares (as of 2018-03-31)
Total Insiders12
Total Directors7
Total Officers5

Stock Insider Trading (from SEC Form 4)

Harvard Apparatus Regenerative Technology, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

HART / Harvard Apparatus Regenerative Technology, Inc. insiders include DST Capital LLC, McGorry James Joseph, Liu Jinhui GREEN DAVID, Canepa John J, McNaughton Thomas, McKee Blaine H., Fodor William, and KENNEDY JOHN F, LaFrancesca Saverio, DerSimonian Harout, Robinson Thomas H, .

Insider Roster

Insider Dir Off 10% Shares Owned
Fodor William Chief Scientific Officer
X 0
Robinson Thomas H Director
X 3,412
McGorry James Joseph Chief Executive Officer, Director
X X 7,965
McNaughton Thomas Chief Financial Officer
X 11,234
Canepa John J Director
X 1,774
McKee Blaine H. Director
X 912
DST Capital LLC 10% Owner
X 525,722
Liu Jinhui 10% Owner
X 736,636
LaFrancesca Saverio President and CMO, Director
X X 293,998
KENNEDY JOHN F Director
X
DerSimonian Harout Chief Scientific Officer
X
GREEN DAVID Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-03-14 4 McKee Blaine H. M D 912 912
2018-03-14 4 Canepa John J M D 912 1,774
2018-03-14 4 McNaughton Thomas M D 928 11,234
2018-03-14 4 McGorry James Joseph M D 1,650 7,965
2018-03-14 4 Robinson Thomas H M D 912 3,412
2018-02-28 4 DST Capital LLC Owned by sole member of reporting person P I 3.26 10,000 525,722 1,713,854
2018-01-22 4 DST Capital LLC Owned by sole member of reporting person P I 2.67 1,572 515,722 1,376,978
2018-01-19 4 DST Capital LLC Owned by sole member of reporting person P I 2.60 3,700 514,150 1,336,790
2018-01-17 4 DST Capital LLC Owned by sole member of reporting person P I 2.20 5,000 510,450 1,122,990
2018-01-12 4 DST Capital LLC Owned by sole member of reporting person P I 2.16 5,000 505,450 1,091,772
2018-01-11 4 DST Capital LLC Owned by sole member of reporting person P I 1.90 200 500,450 950,855
2017-08-24 4 LaFrancesca Saverio P D 0.37 100,000 293,998 108,779
2017-08-23 4 LaFrancesca Saverio P D 0.32 150,000 193,998 62,079
2016-10-12 4 DerSimonian Harout P D 0.91 10,000 10,000 9,100
2016-08-26 4 KENNEDY JOHN F P D 0.929 16,182 58,406 54,259
2016-08-25 4 McGorry James Joseph P D 0.96 25,000 126,300 121,248
2016-06-21 4 McGorry James Joseph P D 1.07 20,000 101,300 108,391
2016-06-13 4 Robinson Thomas H P D 1.1711 32,000 50,000 58,555
2016-05-25 4 Canepa John J P D 1.46 17,241 17,241 25,172
2016-05-20 4 McNaughton Thomas P D 1.56 2,500 409,756 639,219
2016-05-20 4 McNaughton Thomas P D 1.55 2,500 409,756 635,122
2016-05-20 4 KENNEDY JOHN F P D 1.5598 6,500 42,224 65,861
2016-05-20 4 McGorry James Joseph P D 1.56 10,000 81,300 126,828
2016-05-19 4 Robinson Thomas H P D 1.3556 18,000 18,000 24,401
2015-12-17 4 LaFrancesca Saverio P D 2.0131 2,393 43,998 88,572
2015-12-17 4 LaFrancesca Saverio S D 1.9284 -2,393 41,605 80,231
2015-12-01 4 LaFrancesca Saverio P D 3.0052 10,000 43,998 132,223
2015-12-01 4 KENNEDY JOHN F P D 2.9472 9,000 35,724 105,286
2015-11-19 4 McNaughton Thomas P D 1.70 10,000 201,128 341,918
2015-11-19 4 McGorry James Joseph P D 1.79 10,000 71,300 127,627
2015-11-18 4 McNaughton Thomas P D 1.56 10,000 191,128 298,160
2015-11-17 4 McNaughton Thomas P D 1.32 15,000 181,128 239,089
2015-11-17 4 GREEN DAVID P D 1.34 25,000 538,259 721,267
2015-09-18 4 LaFrancesca Saverio P D 1.28 4,500 33,998 43,517
2015-09-18 4 LaFrancesca Saverio P D 1.29 5,000 29,498 38,052
2015-06-30 4 LaFrancesca Saverio J D 1.22 10,284 21,998
2015-08-28 4 LaFrancesca Saverio P D 0.96 2,500 14,214 13,645
2015-08-26 4 McNaughton Thomas P D 0.88 10,000 166,128 146,193
2015-08-24 4 KENNEDY JOHN F P D 0.83 12,000 26,724 22,181
2015-08-21 4 McGorry James Joseph P D 0.75 26,300 61,300 45,975
2015-08-20 4 McGorry James Joseph P D 0.66 5,000 35,000 23,100
2015-08-21 4 McNaughton Thomas P D 0.76 25,000 156,128 118,657
2015-08-19 4 McNaughton Thomas P D 0.62 75,000 131,128 81,299
2015-06-02 4 McGorry James Joseph P D 1.90 20,000 30,000 57,000
2014-04-10 4 McGorry James Joseph P D 8.84 10,000 10,000 88,400
2015-06-04 4 KENNEDY JOHN F P D 2.13 1,000 14,724 31,362
2015-06-03 4 McNaughton Thomas P D 2.01 5,000 56,128 112,817
2015-06-02 4 McNaughton Thomas P D 1.80 8,000 51,128 92,030
2015-06-01 4 McNaughton Thomas P D 1.74 3,000 43,128 75,043
2015-06-03 4 KENNEDY JOHN F P D 1.95 1,000 13,724 26,762
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...